drugset / Trial / NCT02961816
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn about the safety and effectiveness of the combination of panobinostat, gemcitabine, busulfan, and melphalan, either with or without rituximab, in patients who have non-Hodgkin's or Hodgkin's lymphoma and are receiving a stem cell transplant.
Timeline
- Start
- 2017-06
- Primary completion
- 2021-06
- Completion
- 2021-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | — | Intravenous |
| Subject | Gemcitabine | Small molecule | 2700 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Panobinostat | Small molecule | 20 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 8 mg | Intravenous |
| Background | G-CSF | Unknown | — | Subcutaneous |
| Background | Glutamine | Other / unclassified | 15 g | Oral |
| Background | Palifermin | Protein / enzyme biologic | — | Intravenous |
| Background | Pyridoxine | Unknown | 100 mg | Intravenous |